Related Experiment Video
Updated: Jun 19, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Identification of beta2-microglobulin as a potential target for ovarian cancer
Han Shuo Yang1, Yu Li, Hong Xin Deng
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China. yhansh@scu.edu.cn
Abstract:
Ovarian cancer is one of the most lethal gynecological cancers. Antibody-based therapy has emerged as an important therapeutic approach for an increasing number of malignancies. Here, we prepared an antibody pool against SKOV3 ovarian cancer cells, which could induce apoptosis of SKOV3 cells in a dose- and time-dependent manner. Through SEREX analysis, beta 2-microglobulin (b2M) was identified as the potential target molecules of functional antibodies. The immune IgG (i-IgG) of antibody pool had little effects on other kinds of cancer cells, maybe because of the more secretion of b2M by SKOV3. Further studies indicated that specific antibody of b2M indeed also can inhibit the growth of SKOV3. In addition, overexpression of b2M could promote the growth of SKOV3 cells in vitro, by colony formation and anchorage-independent growth assay, at least partially through the activation of PI3K/Akt pathway. Thus, b2M could be a potential therapeutic target in ovarian cancer.
Insights
Researchers developed an antibody pool targeting ovarian cancer cells, identifying beta 2-microglobulin (b2M) as a key molecule. This antibody therapy shows potential for treating ovarian cancer by inhibiting cancer cell growth.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Ovarian cancer remains a highly lethal gynecological malignancy.
- Antibody-based therapies offer a promising avenue for cancer treatment.
- SKOV3 cells are a common model for ovarian cancer research.
Purpose of the Study:
- To develop an antibody pool targeting ovarian cancer cells.
- To identify the specific molecular targets of these antibodies.
- To evaluate the therapeutic potential of targeting beta 2-microglobulin (b2M) in ovarian cancer.
Main Methods:
- Generation of an antibody pool against SKOV3 ovarian cancer cells.
- SEREX analysis to identify antibody targets.
- In vitro assays (colony formation, anchorage-independent growth) to assess cell proliferation.
- Western blot analysis to investigate signaling pathways (PI3K/Akt).
Main Results:
- The antibody pool induced apoptosis in SKOV3 cells in a dose- and time-dependent manner.
- Beta 2-microglobulin (b2M) was identified as a target of the functional antibodies.
- Specific antibodies against b2M inhibited SKOV3 cell growth.
- Overexpression of b2M promoted SKOV3 cell growth, partly via PI3K/Akt pathway activation.
Conclusions:
- Beta 2-microglobulin (b2M) is a potential therapeutic target for ovarian cancer.
- Antibody-mediated targeting of b2M can inhibit ovarian cancer cell growth.
- The PI3K/Akt pathway is involved in b2M-mediated promotion of SKOV3 cell growth.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
